We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorVirbasius, Joseph V.
dc.contributor.authorCzech, Michael P.
dc.date2022-08-11T08:08:19.000
dc.date.accessioned2022-08-23T15:51:06Z
dc.date.available2022-08-23T15:51:06Z
dc.date.issued2016-07-01
dc.date.submitted2016-12-21
dc.identifier.citationTrends Endocrinol Metab. 2016 Jul;27(7):484-92. doi: 10.1016/j.tem.2016.04.006. Epub 2016 May 6. <a href="http://dx.doi.org/10.1016/j.tem.2016.04.006">Link to article on publisher's site</a>
dc.identifier.issn1043-2760 (Linking)
dc.identifier.doi10.1016/j.tem.2016.04.006
dc.identifier.pmid27160798
dc.identifier.urihttp://hdl.handle.net/20.500.14038/28815
dc.description.abstractMitogen-activated kinase kinase kinase kinase 4 (Map4k4), originally identified in small interfering (si)RNA screens and characterized by tissue-specific gene deletions, is emerging as a regulator of glucose homeostasis and cardiovascular health. Recent studies have shown that Map4k4 gene ablation or inhibition of its kinase activity attenuates hyperglycemia and plaque formation in mouse models of insulin resistance and atherosclerosis, and suggest roles for Map4k4 in multiple signaling systems, including NFkappaB activation, small GTPase regulation, the Hippo cascade, and regulation of cell dynamics by FERM domain proteins. This new and promising area of inquiry raises key questions that need to be addressed, such as defining which of the above or other effectors mediate Map4k4 control of metabolic and vascular functions, and identifying upstream activators of Map4k4.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27160798&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.tem.2016.04.006
dc.subjectSterile 20 kinases
dc.subjectatherosclerosis
dc.subjectdiabetes
dc.subjectinsulin resistance
dc.subjectCardiovascular Diseases
dc.subjectCellular and Molecular Physiology
dc.subjectEndocrinology
dc.subjectEndocrinology, Diabetes, and Metabolism
dc.subjectNutritional and Metabolic Diseases
dc.titleMap4k4 Signaling Nodes in Metabolic and Cardiovascular Diseases
dc.typeJournal Article
dc.source.journaltitleTrends in endocrinology and metabolism: TEM
dc.source.volume27
dc.source.issue7
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/1055
dc.identifier.contextkey9493675
html.description.abstract<p>Mitogen-activated kinase kinase kinase kinase 4 (Map4k4), originally identified in small interfering (si)RNA screens and characterized by tissue-specific gene deletions, is emerging as a regulator of glucose homeostasis and cardiovascular health. Recent studies have shown that Map4k4 gene ablation or inhibition of its kinase activity attenuates hyperglycemia and plaque formation in mouse models of insulin resistance and atherosclerosis, and suggest roles for Map4k4 in multiple signaling systems, including NFkappaB activation, small GTPase regulation, the Hippo cascade, and regulation of cell dynamics by FERM domain proteins. This new and promising area of inquiry raises key questions that need to be addressed, such as defining which of the above or other effectors mediate Map4k4 control of metabolic and vascular functions, and identifying upstream activators of Map4k4.</p>
dc.identifier.submissionpathfaculty_pubs/1055
dc.contributor.departmentProgram in Molecular Medicine
dc.source.pages484-92


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record